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Inflammasome has emerged recently as an unexpected sensor for metabolic 
danger and stress. Indeed, it has been implicated in the development of major 
diseases such as gout, type 2 diabetes, and obesity-induced insulin resistance 
and is increasingly suspected of playing a major role in other human 
pathologies such as cancer, asbestosis, and Alzheimer’s disease. The 
inflammasome is a protein complex that comprises an intracellular sensor, 
typically a Nod-like receptor (NLR), the precursor procaspase-1, and the 
adaptor ASC. Inflammasome activation leads to the maturation of caspase-1 
and the processing of its substrates, IL-1b, and IL-18. Of all the NLRs, NLRP3 
is activated by the most diverse array of danger signals. Recently, it has been 
hypothesized the implication of inflammasome in depression and related 
comorbid systemic illnesses, however, was necessary to demonstrate the 
activation of NLRP3 inflammasome in depressive patients. This event was 
intuited because IL-1b, one of the two known cytokines activated by the 
inflammasome complex, has been implicated in stress, depression, and central 
nervous system (CNS) dysregulation. A recent paper published in CNS 
Neuroscience and Therapeutics by Zhang et al. have showed in first time that 
the NLRP3 inflammasome is involved in lipopolysaccharideinduced mice 
depressive-like behaviors. In parallel, the authors of the present paper have 
showed in first time the activation of NLRP3 inflammasome in blood 
mononuclear cells from depressive patients with a high correlation between IL-
1b and IL-18 with Beck Depression Inventory scores of depressive patients. 
These are two papers demonstrating in an animal model and patients, the 
hypothesis of Iwata et al. These findings provide new insight into the 
pathogenesis of major depressive disorder. Now, we must deepen about this 
and study several point involved in the pathogenesis of this disease. 
 
The Mechanism of Disease 
Major depressive disorder is a severe and potentially debilitating psychiatric 
illness that is characterized by a significant change in mood accompanied by 
other symptoms such as low self-esteem, anhedonia, and disrupted sleeping, 
eating, and cognition. Despite the fact that it affects up to 10% of the general 
population worldwide, its pathogenic mechanism remains elusive. 
Consequently, research is now aimed at characterizing its pathophysiology at 
the cellular and molecular level. The first question that we must respond is 
concerning to the events which induce the activation of inflammasome in this 
disease. Psychological stress as inductor of increased IL-1b serum levels has 
been proposed; however, molecular mechanisms by which psychological stress 
could induce activation of inflammasome are unknown. Depression is a very 
common disease in the general population worldwide in which, together to 
environmental factors, it is clear that genetic factors are involved, so in addition 
to psychological stress, we have to look for endogenous events which induce 
inflammasome activation. It could be interesting to investigate the role of 
molecules involved in the pathophysiology of depression, which could have 
potential to induce NLRP3 inflammasome activation.  
Supporting this hypothesis, it has been showed that cortisol correlates with 
increased levels of IL-1b in hypothalamic–pituitary–adrenal (HPA) axis 
dysregulation such as in anorexia nervosa. Because hippocampus has an 
important role in the pathogenesis of depression, it will be interesting to analyze 
the implication and impact of NLRP3 in- flammasome activation in the area of 
hippocampus and neurogenesis, two major changes in this disease known. In 
agreement with these, it has been observed that IL-1b inhibits the differentiation 
of hippocampal neural precursor cells. 
 
Implications in the Treatment of Depression 
The other important question is the implication of inflammasome in the 
treatment of depression. It has been found that antidepressant treatment 
reduces serum levels of IL-1b, but not TNFa, suggesting that IL-1b plays a 
major role in treatment response. We have described that amitriptyline, a 
tricyclic antidepressant, reduce NLRP3 and caspase-1 gene expression, and IL-
1b and IL- 18 serum levels. Other typical treatments of depression are 
monoamine neurotransmitters, selective serotonin reuptake inhibitors (SSRIs), 
and serotonin–noradrenalin reuptake inhibitors; however, the efficacy of these 
treatments remains uncertain showing significant limitations related to 
treatment-resistant depression. So, inflammasome could be a biomarker to 
evaluate the effectiveness and resistant to antidepressants. According to this 
hypothesis, it has been shown that the resistance to SSRI may be driven by the 
pathologically increased IL-1b.  
 
Genetics Implications  
The major goals of personalized medicine are to predict an individual’s 
susceptibility to developing an illness, achieve accurate diagnosis, and optimize 
the most efficient and favorable response to treatment. Mutations and 
polymorphisms in NLR-coding genes or in genetic loci encoding inflammasome-
related proteins correlate with a variety of autoinflammatory diseases and 
propose susceptibility mechanism. In this case, several polymorphisms in the 
two known cytokines activated by the inflammasome complex have shown 
increase the susceptibility to depression in response to stressful life events. 
Therefore, the role of new polymorphisms in NLRP3 or other NLR-coding genes 
could be an interesting new way to evaluate susceptibility profile in depressive 
patients. Future Considerations Personalized medicine holds the hope of 
increasing the likelihood that patients with depression will respond to treatment 
and achieve remission. In agreement with this, the NLRP3 inflammasome 
represents a possible and interesting sensor with potential to offer a 
personalized biomarker that help predict response to particular treatments. 
Furthermore, a dose-dependent screening with several drugs in cells from 
patients may provide profiles of the most indicated treatments in each case. 
Several studies have indicated discrepancies regarding the pathological role of 
inflammation in MDD. These discrepancies could be the result of the presence 
of subgroups of patients with different levels of psychological stress. Anyway, 
NLRP3 inflammasome offers a new perspective in the study of depression, in 
particular, and psychiatric diseases in general. 
 
